脂蛋白(a)在动脉粥样硬化患者中的变化及血脂康干预的影响  

Changes of Lipoprotein (a) in Patients with Atherosclerosis and Effects of Xuezhikang Treatment on Them

作　　者：石湘芸[1] 朱智明[1] 刘英明[1] 吴旭辉[1] 徐洪涛[1] 费宇行[1] 关淑珍[2] 杨希明[2] 韩善桥[2] 李忠安[2] 

机构地区：[1]中国人民解放军海军总医院心内科,北京100037 [2]中国人民解放军海军总医院检验科,北京100037

出　　处：《天津医药》2001年第7期402-403,共2页Tianjin Medical Journal

摘　　要：目的:探讨冠心病(CHD)患者及脑梗死患者血清脂蛋白(a)[Lp(a)]水平及药物干预的影响。方法:151例CHD病人,其中急性心肌梗死(AMI)20例,陈旧性心肌梗死(OMI)49例,心绞痛(AP)82例;脑梗死患者42例及正常对照组30例,测定其血清Lp(a)浓度。对高Lp(a)水平随机分组用血脂康胶囊及维生素C治疗。结果:CHD及脑梗死组其血清LD(a)水平明显高于对照组(均P<0.01);CHD组高于脑梗死组(P<0.01)。CHD组中,AMI组>AP组>OMI组(P<0.01或P<0.05)。用血脂康胶囊4粒/日治疗40例,12周末血清Lp(a)下降19.66％,与治疗前比较差异显著(P<0.05)。结论:提示Lp(a)有致动脉粥样硬化的作用;血脂康胶囊对高血清Lp(a)水平安全有效。To determine the serum levels of lipoproteim (a) LLp(a) J in patients with coronary heart disease (CHD) and coronary infarction and the effect of drug treatment on them. Methods:The Lp (a) concentration was measured in 151 patients with CHD [20 cases of acute myocardial infarction (AMI), 49 cases of old myocardial infarction (OMI) and 82 cases of angina pectoris (AP) ] ,42 patients with cerebral infarction (CI) and 30 normal subjects. Eighty patients with hy-perlipoprotein (a) were treated with Xuezhikang and Vitamin C. Results:The serum levels of Lp (a) in patients with CHD or cerebral infarction were higher than those in control group (P<0.01); those in CHD group were higher than in CI group (P<0.01);in CHD group,their q values were 4.35 in AMI group,3.99 in AP group and 6.36 in OMI group respectively (P<0.01 or P<0.05).Forty patients were treated with Xuezhikang for 4 weeks (4 capsules/day) .their serum levels of Lp (a) were significantly lower than those before treatment (P<0.05). Conclusion:Lp (a) may induce atherosclerosis,and Xuezhikang is an safe and effective antilipernic agent.

关 键 词：脂蛋白(A) 动脉粥样硬化 降血脂药 血脂康 干预 

分 类 号：R543.5[医药卫生—心血管疾病] R972.6[医药卫生—内科学]